Altimmune, Inc. 0A4C.L Stock
Altimmune, Inc. Price Chart
Altimmune, Inc. 0A4C.L Financial and Trading Overview
| Altimmune, Inc. stock price | 8.04 USD |
| Previous Close | 4.08 USD |
| Open | 0 USD |
| Bid | 0 USD x N/A |
| Ask | 0 USD x N/A |
| Day's Range | 0 - 0 USD |
| 52 Week Range | 0 - 23.17 USD |
| Volume | 152 USD |
| Avg. Volume | 16.75K USD |
| Market Cap | N/A |
| Beta (5Y Monthly) | -0.065492 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.389 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0A4C.L Valuation Measures
| Enterprise Value | 41.24M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.2096679 |
| Enterprise Value/Revenue | -522.008 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Altimmune, Inc. Stock Price History
| Beta (5Y Monthly) | -0.065492 |
| 52-Week Change | -50.58% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 23.17 USD |
| 52 Week Low | 0 USD |
| 50-Day Moving Average | 4.62 USD |
| 200-Day Moving Average | 10.8 USD |
0A4C.L Share Statistics
| Avg. Volume (3 month) | 16.75K USD |
| Avg. Daily Volume (10-Days) | 1.07K USD |
| Shares Outstanding | N/A |
| Float | 42.61M |
| Short Ratio | N/A |
| % Held by Insiders | 0.83% |
| % Held by Institutions | 92.84% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 111562.02% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -28.050% |
| Return on Equity (ttm) | -48.41% |
Income Statement
| Revenue (ttm) | -79000 USD |
| Revenue Per Share (ttm) | -0.002 USD |
| Quarterly Revenue Growth (yoy) | -34.39% |
| Gross Profit (ttm) | -70520000 USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -85357000 USD |
| Diluted EPS (ttm) | -2.389 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 165.73M USD |
| Total Cash Per Share (mrq) | 3.36 USD |
| Total Debt (mrq) | 1.02M USD |
| Total Debt/Equity (mrq) | 0.61 USD |
| Current Ratio (mrq) | 11.579 |
| Book Value Per Share (mrq) | 3.403 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -68467000 USD |
| Levered Free Cash Flow (ttm) | -47639752 USD |
Profile of Altimmune, Inc.
| Country | United Kingdom |
| State | MD |
| City | Gaithersburg |
| Address | 910 Clopper Road |
| ZIP | 20878 |
| Phone | 240 654 1450 |
| Website | https://altimmune.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 52 |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Q&A For Altimmune, Inc. Stock
What is a current 0A4C.L stock price?
Altimmune, Inc. 0A4C.L stock price today per share is 8.04 USD.
How to purchase Altimmune, Inc. stock?
You can buy 0A4C.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Altimmune, Inc.?
The stock symbol or ticker of Altimmune, Inc. is 0A4C.L.
How many shares does Altimmune, Inc. have in circulation?
The max supply of Altimmune, Inc. shares is 0.
What is Altimmune, Inc. Price to Earnings Ratio (PE Ratio)?
Altimmune, Inc. PE Ratio is now.
What was Altimmune, Inc. earnings per share over the trailing 12 months (TTM)?
Altimmune, Inc. EPS is -2.389 USD over the trailing 12 months.